menu
    • menu

    Company profile for Shanghai Hengrui Pharmaceutical

    NEW Drugs in Dev: 36
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Shanghai Hengrui Medicine Co., Ltd. is a joint venture established by Jiangsu Hengrui Medicine Co., Ltd. and Hong Kong Hongchuang Technology Co., Ltd., with a registered capital of 72 million yuan. The company is located in Shanghai Minhang Economic and Technological Development Zone, covering an area of ​​80 acres, with a high-level scientific research and experimental base and a high-level GMP production workshop.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Shanghai Hengrui PharmaceuticalChina Flag
    Country
    Country
    China
    Address
    Address
    No. 279, Wenjing Road, Economic and Technological Development Zone, Minhang Di...
    Telephone
    Telephone
    +86-2123511999
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.shhrp.com/contact.html
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Hengrui Pharma, Kailera Therapeutics Present Clinical Data
    Hengrui Pharma, Kailera Therapeutics Present Clinical Data

    13 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/13/3293890/0/en/hengrui-pharma-and-kailera-therapeutics-announce-clinical-data-presentations-at-the-american-diabetes-association-86th-scientific-sessions.html

    GLOBENEWSWIRE
    13 May 2026
    Share Share
    Hengrui Pharma's Q1 2026 Profit Meets Expectations
    Hengrui Pharma's Q1 2026 Profit Meets Expectations

    22 Apr 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-top-drugmaker-hengrui-profit-line-with-expectations-first-quarter-2026-2026-04-22/

    REUTERS
    22 Apr 2026
    Share Share
    Glenmark, Hengrui ink $1.1B deal for HER2 ADC
    Glenmark, Hengrui ink $1.1B deal for HER2 ADC

    24 Sep 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/potential-11b-deal-glenmark-grabs-certain-rights-hengrui-adc-rival-enhertu

    FIERCE PHARMA
    24 Sep 2025
    Share Share
    Jiangsu Hengrui Grants GSK global rights to Drug portfolio
    Jiangsu Hengrui Grants GSK global rights to Drug portfolio

    29 Jul 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/jiangsu-hengrui-grants-gsk-global-rights-drug-portfolio-500-million-deal-2025-07-28/

    REUTERS
    29 Jul 2025
    Share Share
    IDEAYA, Hengrui to Present IDE849 (SHR-4849) Data at IASLC 2025
    IDEAYA, Hengrui to Present IDE849 (SHR-4849) Data at IASLC 2025

    22 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-and-hengrui-pharmaceuticals-announce-oral-presentation-at-iaslc-2025-world-conference-on-lung-cancer-for-ide849-shr-4849-a-potential-first-in-class-dll3-top1-adc-302510323.html

    PR NEWSWIRE
    22 Jul 2025
    Share Share
    Hengrui Pharma Highlights Chinese Cancer Innovation at 2025 ASCO
    Hengrui Pharma Highlights Chinese Cancer Innovation at 2025 ASCO

    05 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hengrui-pharma-showcases-global-impact-at-the-2025-asco-72-study-results-highlight-chinese-cancer-innovation-302474128.html

    PR NEWSWIRE
    05 Jun 2025
    Share Share

    FDF Dossiers

    read-more
    read-more

    01

    Brand Name : DESFLURANE

    China
    PEGS Boston Summit
    Not Confirmed
    arrow

    Brand Name : DESFLURANE

    China
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : RX

    Registration Country : USA

    DESFLURANE

    Shanghai Hengrui Pharmaceutical

    Dosage Form : LIQUID;INHALATION

    Brand Name : DESFLURANE

    Dosage Strength : 100%

    Packaging :

    Approval Date : 2018-02-26

    Application Number : 208234

    Regulatory Info : RX

    Registration Country : USA

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : SEVOFLURANE

    China
    PEGS Boston Summit
    Not Confirmed
    arrow

    Brand Name : SEVOFLURANE

    China
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : RX

    Registration Country : USA

    SEVOFLURANE

    Shanghai Hengrui Pharmaceutical

    Dosage Form : LIQUID;INHALATION

    Brand Name : SEVOFLURANE

    Dosage Strength : 100%

    Packaging :

    Approval Date : 2015-11-03

    Application Number : 203793

    Regulatory Info : RX

    Registration Country : USA

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    Inspections and registrations

    Upload your audits for free, ask us

    FDA

    read-more
    read-more

    01

    FDA Audited

    USA
    PEGS Boston Summit
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    PEGS Boston Summit
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2025-04-04

    Shanghai Hengrui Pharmaceutical

    City : Lianyungang

    State :

    Country/Area : China

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2025-04-04

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    02

    FDA Audited

    USA
    PEGS Boston Summit
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    PEGS Boston Summit
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2024-10-25

    Shanghai Hengrui Pharmaceutical

    City : Shanghai

    State :

    Country/Area : China

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2024-10-25

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    03

    FDA Audited

    USA
    PEGS Boston Summit
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    PEGS Boston Summit
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2024-01-19

    Shanghai Hengrui Pharmaceutical

    City : Lianyungang

    State :

    Country/Area : China

    Zip :

    District :

    Center :

    Project Area : Bioresearch Monitoring

    District Decision : No Action Indicated

    Inspection End Date : 2024-01-19

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    04

    FDA Audited

    USA
    PEGS Boston Summit
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    PEGS Boston Summit
    Not Confirmed

    District Decision : Official Action Indicated

    Inspection End Date : 2024-01-16

    Shanghai Hengrui Pharmaceutical

    City : Lianyungang

    State :

    Country/Area : China

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : Official Action Indicated

    Inspection End Date : 2024-01-16

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    05

    FDA Audited

    USA
    PEGS Boston Summit
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    PEGS Boston Summit
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2018-07-20

    Shanghai Hengrui Pharmaceutical

    City : Shanghai

    State :

    Country/Area : China

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2018-07-20

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    06

    FDA Audited

    USA
    PEGS Boston Summit
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    PEGS Boston Summit
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2018-05-14

    Shanghai Hengrui Pharmaceutical

    City : Lianyungang

    State :

    Country/Area : China

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2018-05-14

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    07

    FDA Audited

    USA
    PEGS Boston Summit
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    PEGS Boston Summit
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2016-11-02

    Shanghai Hengrui Pharmaceutical

    City : Lianyungang

    State :

    Country/Area : China

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2016-11-02

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    08

    FDA Audited

    USA
    PEGS Boston Summit
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    PEGS Boston Summit
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2015-03-27

    Shanghai Hengrui Pharmaceutical

    City : Shanghai

    State :

    Country/Area : China

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2015-03-27

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    09

    FDA Audited

    USA
    PEGS Boston Summit
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    PEGS Boston Summit
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2014-05-13

    Shanghai Hengrui Pharmaceutical

    City : Lianyungang

    State :

    Country/Area : China

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2014-05-13

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    10

    FDA Audited

    USA
    PEGS Boston Summit
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    PEGS Boston Summit
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2013-09-06

    Shanghai Hengrui Pharmaceutical

    City : Shanghai

    State :

    Country/Area : China

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2013-09-06

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search